title: [Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years].
abstract: We report the case of a 72-year-old woman who was diagnosed in 2006 with renal cell cancer (RCC) and had undergone consecutive tumor nephrectomy (clear-cell RCC, Fuhrmann grade II, stage pT3a, R0). Over the years, the patient underwent several surgical and radiological interventions due to various metastatic lesions. This case report describes the 3-year progression-free survival in a patient who underwent first-line therapy with the monoclonal antibody bevacizumab. Except for hypertension, the patient does not suffer currently from any other side effects of bevacizumab therapy.
authors.affiliation: Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. Renate.Pichler@i-med.ac.at.
authors.forename: R
authors.initials: R
authors.lastname: Pichler
authors.affiliation: Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich.
authors.forename: W
authors.initials: W
authors.lastname: Horninger
authors.affiliation: Universitätsklinik für Radiologie, Medizinische Universität Innsbruck, Innsbruck, Österreich.
authors.forename: F
authors.initials: F
authors.lastname: Aigner
authors.affiliation: Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich.
authors.forename: I
authors.initials: I
authors.lastname: Heidegger
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: Hypertension; Metastases resection, sequential; Neoplasm metastasis; Proteinuria; Tumor nephrectomy